Related Experiment Video

Updated: Jun 1, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Targeting 5α-reductase for prostate cancer prevention and treatment

Lucas P Nacusi1, Donald J Tindall

  • 1Department of Urology Research, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA.

Nature Reviews. Urology
|June 2, 2011
PubMed

Insights

Androgen deprivation therapy is standard for prostate cancer, but resistance emerges. 5α-reductase inhibitors show promise in reducing cancer incidence but may increase aggressiveness, leaving optimal use unclear.

Area of Science:

  • Oncology
  • Endocrinology
  • Urology

Background:

  • Prostate cancer treatment relies on reducing androgens, like testosterone, and blocking the androgen receptor (AR).
  • Current therapies often lead to inevitable cancer recurrence due to resistance mechanisms.
  • Targeting the androgen-AR axis offers potential for improved prostate cancer management.

Purpose of the Study:

  • To evaluate the role of 5α-reductase inhibitors (5ARIs) in prostate cancer prevention and treatment.
  • To understand the impact of 5ARIs on prostate cancer aggressiveness.

Main Methods:

  • Review of major clinical trials investigating 5α-reductase inhibitors (finasteride, dutasteride) in prostate cancer.
  • Analysis of cancer incidence and tumor aggressiveness in patients treated with 5ARIs versus placebo.

Main Results:

  • 5ARI treatment significantly reduced the overall incidence of prostate cancer.
  • Detected prostate cancers in the 5ARI groups were more aggressive compared to the placebo group.
  • The optimal clinical application of 5ARIs for prostate cancer remains undetermined.

Conclusions:

  • While 5ARIs can decrease prostate cancer incidence, their effect on tumor aggressiveness requires careful consideration.
  • Further research is needed to clarify the best practices for utilizing 5ARIs in prostate cancer prevention and therapy.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...